熱門資訊> 正文
欧盟批准膀胱癌治疗后，ImmunityBio上升
2026-02-18 23:06
- ImmunityBio (IBRX) traded higher on Wednesday after the European Commission issued a conditional marketing authorization for its bladder cancer therapy, Anktiva, expanding its use in more than two dozen EU countries.
- The decision came after an expert panel of the EU drug regulator, the European Medicines Agency, endorsed the immunotherapy in December as part of a combination regimen for a type of invasive bladder cancer.
- Specifically, the authorization allows the company to market Anktiva across 27 countries in combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer.
- As part of the condition approval, which was based on IBRX’s Phase 2/3 QUILT-3.032 study, ImmunityBio (IBRX) is required to provide EU regulators with long-term safety and efficacy data related to Anktiva.
More on ImmunityBio
- ImmunityBio: The Story Surrounding Anktiva So Far
- ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade)
- ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- ImmunityBio rally causes $492M paper losses for short sellers
- ImmunityBio extends gains after FDA views on Anktiva label expansion
推薦文章
美股機會日報 | 特朗普再放豪言！正與伊朗談判，並收到伊方「大禮」；特斯拉機器人再迎新進展！馬斯克稱有望明年實現量產
一圖看懂 | 單季盈利承壓！拼多多Q4營收1239億元同比增12%，調后淨利卻下跌12%；高管稱「力爭三年再造一個拼多多」
財報前瞻 | 美團Q4財報將放榜！大摩、高盛逆勢力挺股價，當前美團已嚴重超跌？
中東戰火中金價狂瀉11%！創43年最慘周跌，避險邏輯崩塌還是黃金坑？
美股機會日報 | 中東硝煙將散？以官員稱美方4月9日結束對伊戰爭！海力士擬籌資百億赴美上市，豪擲80億美元鎖定阿斯麥光刻機！
一圖看懂 | 連續5個季度破千億！小米Q4營收1169億創歷史新高；淨利大增43.8%至63億元
無論美伊談判真假！華爾街已從特朗普引發的五分鍾狂飆獲得明確信號？
麥格理：緊張局勢緩和后布倫特原油底部在每桶85至90美元
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
